Cysteine proteases: Battling pathogenic parasitic protozoans with omnipresent enzymes

Area of Science:

• Parasitology
• Molecular Biology
• Drug Discovery

Background:

• Parasitic protozoan infections cause significant global mortality, with rising drug resistance limiting treatment options.
• Cysteine proteases are crucial for protozoan pathogen survival and are druggable targets, yet remain underexplored clinically.
• Malaria, amoebiasis, and leishmaniasis, caused by Plasmodium, Entamoeba, and Leishmania, respectively, represent major protozoan disease burdens.

Purpose of the Study:

• To review the role of cysteine proteases in Plasmodium, Entamoeba, and Leishmania pathogenesis.
• To highlight cysteine proteases as promising therapeutic targets for protozoan diseases.
• To explore the potential of molecular tools like CRISPR-Cas for studying these enzymes and protozoan function.

Main Methods:

• Literature review focusing on cysteine proteases in Plasmodium, Entamoeba, and Leishmania.
• Analysis of current therapeutic challenges and drug resistance mechanisms.
• Discussion of CRISPR-Cas technology for genomic exploration and functional studies.

Main Results:

• Cysteine proteases are essential for the lifecycle and virulence of key protozoan parasites.
• Existing therapies face challenges due to widespread drug resistance.
• CRISPR-Cas technology offers a powerful approach to investigate protozoan biology and validate cysteine proteases as drug targets.

Conclusions:

• Targeting cysteine proteases is a viable strategy to combat parasitic protozoan infections.
• Advancements in molecular tools are crucial for understanding protozoan enzymes and developing novel diagnostics and therapeutics.
• Overcoming research hurdles is essential for managing the global burden of these diseases.